Advertisement

The Immunopathogenesis and Immunopathology of Systemic Lupus Erythematosus

Chapter

Abstract

Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by the production of antinuclear antibodies (ANAs). These antibodies can bind protein and nucleic acid components of the cell nucleus to form immune complexes to drive pathogenesis. These complexes can deposit in the kidney to incite nephritis or stimulate plasmacytoid dendritic cells (pDCs) to produce cytokines, most prominently type 1 interferon. The activity of the complexes reflects the intrinsic immunostimulatory properties of nucleic acids, both DNA and RNA, which can activate the innate immune system by interaction with toll-like receptors (TLRs) as well as non-TLR sensors. The operation of this system requires the presence of extracellular nucleic acids which can be derived from apoptotic and necrotic cells. With impaired clearance of dead and dying cells, levels of extracellular nucleic acids can rise and intensify immune disturbances key to autoimmunity.

Keywords

Systemic Lupus Erythematosus Immune Complex Autoantibody Production Congenital Heart Block Human Lupus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Sources

  1. 1.
    Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526–33.PubMedCrossRefGoogle Scholar
  2. 2.
    Ardoin SP, Pisetsky DS. Developments in the scientific understanding of lupus. Arthritis Res Ther. 2008;10(5):218.PubMedCrossRefGoogle Scholar
  3. 3.
    Boulé MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med. 2005;199(12):1631–40.CrossRefGoogle Scholar
  4. 4.
    Chaussabel D, Quinn C, Shen J, et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity. 2008;29:150–64.PubMedCrossRefGoogle Scholar
  5. 5.
    Crispin JC, Kyttaris VC, Juang Y-T, Tsokos GC. How signaling and gene transcription aberrations dictate the systemic lupus eruthematosus T cell phenotype. Trends Immunol. 2008;29(3):110–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Hom G, Graham RR, Modrek B, et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med. 2008;358:1–10.CrossRefGoogle Scholar
  7. 7.
    Huerta PT, Kowal C, DeGiorgio LA, Volpe BT, Diamond B. Immunity and behavior: antibodies alter emotion. Proc Natl Acad Sci U S A. 2006;103(3):678–83.PubMedCrossRefGoogle Scholar
  8. 8.
    Jǿrgensen TN, Gubbels MR, Kotzin BL. New insights into disease pathogenesis from mouse lupus genetics. Curr Opin Immunol. 2004;16:787–93.PubMedCrossRefGoogle Scholar
  9. 9.
    Kelly KM, Zhuang H, Nacionales DC, et al. “Endogenous adjuvant” activity of the RNA components of lupus autoantigens Sm/RNP and Ro 60. Arthritis Rheum. 2006;54(5):1557–67.PubMedCrossRefGoogle Scholar
  10. 10.
    Lafyatis R, Marshak-Rothstein A. Toll-like receptors and innate immune responses in systemic lupus erythematosus. Arthritis Res Ther. 2007;9(6):1–7.CrossRefGoogle Scholar
  11. 11.
    Lauwerys BR, Wakeland EK. Genetics of lupus nephritis. Lupus. 2005;14:2–12.PubMedCrossRefGoogle Scholar
  12. 12.
    Mortensen ES, Fenton KA, Rekvig OP. Lupus nephritis: the central role of nucleosomes revealed. Am J Pathol. 2008;172(2):275–83.PubMedCrossRefGoogle Scholar
  13. 13.
    Muller S, Dieker J, Tincani A, Meroni PL. Pathogenic anti-nucleosome antibodies. Lupus. 2008;17:431–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Munoz LE, Lauber K, Schiller M, Manfredi AA, Hermann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol. 2010;6(5):280–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Odendahl M, Jacobi A, Hansen A, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol. 2000;165:5970–9.PubMedGoogle Scholar
  16. 16.
    Pisetsky DS. Immune responses to DNA in normal and aberrant immunity. Immunol Res. 2000;22(2–3):119–26.PubMedCrossRefGoogle Scholar
  17. 17.
    Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358(9):929–39.PubMedCrossRefGoogle Scholar
  18. 18.
    Seshan SV, Jennette JC. Renal disease in systemic lupus erythematosus with emphasis on classification of lupus glomerulonephritis. Arch Pathol Lab Med. 2009;133:233–48.PubMedGoogle Scholar
  19. 19.
    Shlomchik MJ. Activating systemic autoimmunity: B’s, T’s and tolls. Curr Opin Immunol. 2009;21(6):626–33.PubMedCrossRefGoogle Scholar
  20. 20.
    Yurasov S, Wardemann H, Hammersen J, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med. 2005;201(5):703–11.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Department of Medicine and ImmunologyDuke University Medical CenterDurhamUSA
  2. 2.Medical Research ServiceDurham VA HospitalDurhamUSA

Personalised recommendations